Know Cancer

or
forgot password

Development of Novel Therapeutics for AMKL


N/A
N/A
N/A
Not Enrolling
Both
Leukemia

Thank you

Trial Information

Development of Novel Therapeutics for AMKL


OBJECTIVES:

- Determine whether megakaryocyte differentiation agents comprising a Rho kinase
inhibitor and a JAK3 inhibitor can lead to proliferation arrest, polyploidization, and
terminal differentiation of blasts in specimens from patients with Down syndrome and
acute megakaryoblastic leukemia.

OUTLINE: Cryopreserved specimens are cultured and treated in vivo (in mice) and in vitro
with megakaryocytic differentiation agents comprising a Rho kinase inhibitor and a JAK3
inhibitor.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Diagnosis of acute megakaryoblastic leukemia

- Diagnosis of Down syndrome

- Cryopreserved specimens available

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- Not specified

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Proliferation arrest

Safety Issue:

No

Principal Investigator

John Crispino, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Robert H. Lurie Cancer Center

Authority:

United States: Federal Government

Study ID:

CDR0000671427

NCT ID:

NCT01139307

Start Date:

July 2009

Completion Date:

Related Keywords:

  • Leukemia
  • adult acute megakaryoblastic leukemia (M7)
  • childhood acute megakaryocytic leukemia (M7)
  • recurrent adult acute myeloid leukemia
  • recurrent childhood acute myeloid leukemia
  • untreated adult acute myeloid leukemia
  • untreated childhood acute myeloid leukemia and other myeloid malignancies
  • Leukemia
  • Leukemia, Megakaryoblastic, Acute

Name

Location